BioSpace News Archive

eMolecules, Inc., provider of a leading chemistry search-and-fulfillment platform for early drug discovery research, announced the acquisitions of Frontier Scientific Inc. and Frontier Agricultural Sciences Inc. Financial terms of the transactions were not disclosed.

Medline has invested an additional $500 million in incremental medical supply inventory to ensure product availability and timely delivery to the healthcare providers it serves.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch, in the U.S. market, of Lenalidomide Capsules, a therapeutic equivalent generic version of REVLIMID® (lenalidomide) Capsules approved by U.S. Food and Drug Administration (USFDA).

Veru Inc. announced that the U.S. Food and Drug Administration has informed the Company that FDA’s Pulmonary-Allergy Drugs Advisory Committee will meet to discuss the Company’s request for Emergency Use Authorization of sabizabulin for hospitalized COVID-19 patients at high risk for ARDS.

Indivior PLC announced that it will participate in the following investor healthcare events.

NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, today announced that its senior management will present at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, in New York City.

CCRF recently awarded two promising scientists the Emerging Scientist Award at the University of Minnesota.

A recent study on Apos®, a medical device that treats chronic knee conditions, could have significant implications on the cost, pain, and quality-of-life problems associated with knee osteoarthritis (OA).

Client billing for clinical laboratories and pathology groups has traditionally included time-consuming, mostly manual processes that often led to mistakes and delays in payment for services rendered.

Novo Nordisk introduced Ozempic to the market in 2017, giving Type 2 diabetics a different option when it comes to their injections made for keeping their blood sugar levels down and managing their diabetes effectively.